Data from Protalex' Phase I Clinical Trial of PRTX-100 Presented at the American College of Clinical Pharmacology.

NEW HOPE, Pa. -- Protalex, Inc. (OTCBB:PRTX) today announced that data from its Phase I clinical trial of PRTX-100 was presented at the American College of Clinical Pharmacology meeting in Boston, MA on September 17, 2006. The abstract was entitled: Phase I study of the safety and pharmacokinetics of staphylococcal protein A in healthy adults. PRTX-100 is in development for autoimmune disorders including rheumatoid arthritis and idiopathic thrombocytopenic purpura (ITP), a disorder in which the blood does not clot.

As previously announced, the data demonstrated that in a single dose Phase I clinical trial, PRTX 100 was safe and well tolerated. There were no serious adverse events deaths and no major safety lab or vital sign abnormalities. All 36 volunteers who enrolled in the study completed the trial.

The company plans to meet with the United States Food and Drug Administration during the fourth quarter and expects to file an investigational new drug application for PRTX-100 in ITP. Protalex anticipates proceeding to a Phase II clinical trial in the ITP indication in early 2007.

About PRTX-100

PRTX-100 is a highly-purified form of Staphylococcal Protein A. PRTX-100 binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases, enabling the compound to modulate the function of these cells and restore the balance of the immune system.

About Protalex, Inc.

Protalex, Inc. is a biotechnology company engaged in the development of a new class of drugs for the treatment of Rheumatoid Arthritis (RA), Idiopathic Thrombocytopenic Purpura (ITP) and a host of other autoimmune disorders. Additional information about Protalex, Inc. can be found at www.protalex.com.

Cautionary Statement Regarding Forward Looking Information

This release contains forward-looking information about Protalex, Inc. that are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Protalex's future performance, operations and products.

This forward-looking information should be considered only in connection with "Risk Factors" in Protalex's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission ("SEC") on July 28, 2006 and its other periodic reports filed with the SEC. Protalex assumes no obligation to update any forward-looking statements or information set forth in this press release.